Haemonetics Corporation Company Profile (NYSE:HAE)

About Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:HAE
  • CUSIP: 40502410
  • Web: www.haemonetics.com
Capitalization:
  • Market Cap: $2.22472 billion
  • Outstanding Shares: 52,606,000
Average Prices:
  • 50 Day Moving Avg: $42.15
  • 200 Day Moving Avg: $40.89
  • 52 Week Range: $32.76 - $43.77
P/E:
  • Trailing P/E Ratio: 548.70
  • Foreward P/E Ratio: 23.47
  • P/E Growth: 3.19
Sales & Book Value:
  • Annual Revenue: $887.11 million
  • Price / Sales: 2.51
  • Book Value: $14.71 per share
  • Price / Book: 2.87
Profitability:
  • EBIDTA: $164.54 million
  • Net Margins: 0.48%
  • Return on Equity: 11.07%
  • Return on Assets: 6.54%
Debt:
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 2.57%
  • Quick Ratio: 1.72%
Misc:
  • Average Volume: 324,152 shs.
  • Beta: 0.89
  • Short Ratio: 9.35
 

Frequently Asked Questions for Haemonetics Corporation (NYSE:HAE)

What is Haemonetics Corporation's stock symbol?

Haemonetics Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How were Haemonetics Corporation's earnings last quarter?

Haemonetics Corporation (NYSE:HAE) issued its earnings results on Monday, August, 7th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.31 by $0.02. The firm earned $211 million during the quarter, compared to the consensus estimate of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The business's quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.25 earnings per share. View Haemonetics Corporation's Earnings History.

When will Haemonetics Corporation make its next earnings announcement?

Haemonetics Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Haemonetics Corporation.

Where is Haemonetics Corporation's stock going? Where will Haemonetics Corporation's stock price be in 2017?

7 equities research analysts have issued 12 month target prices for Haemonetics Corporation's shares. Their predictions range from $24.00 to $50.00. On average, they anticipate Haemonetics Corporation's stock price to reach $39.83 in the next year. View Analyst Ratings for Haemonetics Corporation.

Who are some of Haemonetics Corporation's key competitors?

Who are Haemonetics Corporation's key executives?

Haemonetics Corporation's management team includes the folowing people:

  • Christopher Simon, President, Chief Executive Officer, Director
  • William P. Burke, Chief Financial Officer, Executive Vice President
  • Michelle Basil, Executive Vice President, General Counsel
  • Neil Ryding, Executive Vice President, Global Operations
  • Richard J. Meelia, Non-Executive Independent Chairman of the Board
  • Catherine M. Burzik, Independent Director
  • Charles J. Dockendorff, Independent Director
  • Susan Bartlett Foote, Independent Director
  • Ronald G. Gelbman, Independent Director

Who owns Haemonetics Corporation stock?

Haemonetics Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.92%), Vanguard Group Inc. (9.03%), Wells Fargo & Company MN (5.31%), Victory Capital Management Inc. (3.87%), Neuberger Berman Group LLC (3.55%) and HealthCor Management L.P. (3.53%). Company insiders that own Haemonetics Corporation stock include Byron Selman, Christopher J Lindop, Christopher Simon, Ronald G Gelbman, Ronald Merriman, Sandra Jesse and Susan M Hanlon. View Institutional Ownership Trends for Haemonetics Corporation.

Who sold Haemonetics Corporation stock? Who is selling Haemonetics Corporation stock?

Haemonetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, Thrivent Financial For Lutherans, American Capital Management Inc., BTIM Corp., Goldman Sachs Group Inc. and Heartland Advisors Inc.. Company insiders that have sold Haemonetics Corporation stock in the last year include Ronald G Gelbman and Ronald Merriman. View Insider Buying and Selling for Haemonetics Corporation.

Who bought Haemonetics Corporation stock? Who is buying Haemonetics Corporation stock?

Haemonetics Corporation's stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC, Arrowstreet Capital Limited Partnership, Ameriprise Financial Inc., Renaissance Technologies LLC, Balyasny Asset Management LLC and Van Berkom & Associates Inc.. View Insider Buying and Selling for Haemonetics Corporation.

How do I buy Haemonetics Corporation stock?

Shares of Haemonetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics Corporation's stock price today?

One share of Haemonetics Corporation stock can currently be purchased for approximately $42.25.


MarketBeat Community Rating for Haemonetics Corporation (NYSE HAE)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Haemonetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Haemonetics Corporation (NYSE:HAE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $39.83 (5.72% downside)

Analysts' Ratings History for Haemonetics Corporation (NYSE:HAE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Barrington ResearchUpgradeMarket Perform -> Outperform$48.00HighView Rating Details
7/27/2017Jefferies Group LLCReiterated RatingBuy$48.00HighView Rating Details
7/13/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$50.00HighView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016Benchmark Co.Boost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$29.00N/AView Rating Details
5/12/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/23/2015Raymond James Financial, Inc.DowngradeMarket Perform -> UnderperformN/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Haemonetics Corporation (NYSE:HAE)
Earnings by Quarter for Haemonetics Corporation (NYSE:HAE)
Earnings History by Quarter for Haemonetics Corporation (NYSE HAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017        
8/7/2017Q1 2018$0.31$0.33$211.29 million$211.00 millionViewListenView Earnings Details
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Haemonetics Corporation (NYSE:HAE)
2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.59
2019 EPS Consensus Estimate: $1.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.37$0.42$0.39
Q4 20173$0.35$0.38$0.36
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.43$0.47$0.45
Q4 20182$0.41$0.41$0.41
Q1 20191$0.25$0.25$0.25
Q2 20191$0.45$0.45$0.45
Q3 20191$0.47$0.47$0.47
Q4 20191$0.42$0.42$0.42
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics Corporation (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Haemonetics Corporation (NYSE:HAE)
Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.43View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.90View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.18View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Haemonetics Corporation (NYSE:HAE)
Latest Headlines for Haemonetics Corporation (NYSE:HAE)
Source:
DateHeadline
finance.yahoo.com logoHaemonetics Appoints David J. Wilson Plasma Business Unit President
finance.yahoo.com - September 14 at 7:59 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Expected to Post Quarterly Sales of $219.67 Million
www.americanbankingnews.com - September 11 at 10:00 AM
americanbankingnews.com logo Analysts Anticipate Haemonetics Corporation (HAE) Will Post Earnings of $0.42 Per Share
www.americanbankingnews.com - September 9 at 10:42 AM
finanznachrichten.de logoFrank Magliochetti - Highlights the Potential of Wearable Sensors in Healthcare Diagnosis
www.finanznachrichten.de - August 31 at 5:15 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 30 at 12:44 AM
finance.yahoo.com logoHaemonetics to Present at Morgan Stanley's Global Healthcare Conference
finance.yahoo.com - August 29 at 7:51 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 29 at 5:52 PM
americanbankingnews.com logoJefferies Group Research Analysts Reduce Earnings Estimates for Haemonetics Corporation (HAE)
www.americanbankingnews.com - August 28 at 11:22 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 24 at 1:38 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 23 at 3:28 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Haemonetics Corporation (HAE) to Post $0.42 EPS
www.americanbankingnews.com - August 21 at 10:20 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 16 at 3:48 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Haemonetics Corp.
finance.yahoo.com - August 11 at 1:34 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Haemonetics Corporation's Q3 2018 Earnings (NYSE:HAE)
www.americanbankingnews.com - August 10 at 12:38 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Rating Increased to B- at TheStreet
www.americanbankingnews.com - August 9 at 9:10 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Upgraded to "Outperform" by Barrington Research
www.americanbankingnews.com - August 8 at 8:30 AM
finance.yahoo.com logoEdited Transcript of HAE earnings conference call or presentation 7-Aug-17 12:00pm GMT
finance.yahoo.com - August 8 at 1:47 AM
rttnews.com logoHaemonetics Posts Profit In Q1, Above Market; Revenues Miss Estimates
www.rttnews.com - August 7 at 3:43 PM
seekingalpha.com logoHaemonetics (HAE) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 3:43 PM
reuters.com logoBRIEF-Haemonetics Corp reports Q1 earnings per share $0.38
www.reuters.com - August 7 at 3:42 PM
finance.yahoo.com logoHaemonetics 1st Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - August 7 at 3:42 PM
finance.yahoo.com logoHaemonetics tops 1Q profit forecasts
finance.yahoo.com - August 7 at 3:42 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 7 at 8:50 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $213.55 Million
www.americanbankingnews.com - August 5 at 7:08 AM
americanbankingnews.com logoHaemonetics Corporation (NYSE:HAE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 5 at 12:40 AM
finance.yahoo.com logoHaemonetics Corp. – Value Analysis (NYSE:HAE) : August 5, 2017
finance.yahoo.com - August 5 at 12:38 AM
finance.yahoo.com logoWhy Earnings Season Could Be Great for Haemonetics (HAE)
finance.yahoo.com - August 3 at 7:21 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Expected to Post Earnings of $0.31 Per Share
www.americanbankingnews.com - August 3 at 6:10 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 7:54 AM
prnewswire.com logoHaemonetics Announces FDA Clearance of New Plasmapheresis System Branded ...
www.prnewswire.com - July 29 at 3:05 AM
finance.yahoo.com logoHaemonetics Announces FDA Clearance of New Plasmapheresis System Branded NexSys PCS™
finance.yahoo.com - July 28 at 10:04 PM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for Haemonetics Corporation (NYSE:HAE)
www.americanbankingnews.com - July 27 at 6:52 PM
americanbankingnews.com logoReviewing Haemonetics Corporation (NYSE:HAE) and DENTSPLY SIRONA (XRAY)
www.americanbankingnews.com - July 25 at 10:19 PM
finance.yahoo.com logoHaemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : July 24, 2017
finance.yahoo.com - July 24 at 10:00 PM
finance.yahoo.com logoHaemonetics Sets Date for Publishing 1st Quarter Fiscal 2018 Results: August 7, 2017
finance.yahoo.com - July 18 at 9:17 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Rating Increased to Outperform at JMP Securities
www.americanbankingnews.com - July 16 at 7:02 PM
americanbankingnews.com logoHaemonetics Corporation (NYSE:HAE) Expected to Post Quarterly Sales of $213.55 Million
www.americanbankingnews.com - July 14 at 2:06 PM
finance.yahoo.com logoBelieve In The Haemonetics Turnaround Story; JMP Upgrades To Market Outperform
finance.yahoo.com - July 13 at 8:59 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM
americanbankingnews.com logo Brokerages Anticipate Haemonetics Corporation (HAE) to Announce $0.31 Earnings Per Share
www.americanbankingnews.com - July 12 at 12:56 PM
americanbankingnews.com logoHaemonetics Corporation (HAE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 11 at 12:40 AM
finance.yahoo.com logoETFs with exposure to Haemonetics Corp. : July 6, 2017
finance.yahoo.com - July 7 at 5:58 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Lowered to Sell at BidaskClub
www.americanbankingnews.com - June 23 at 9:00 PM
finance.yahoo.com logoHaemonetics Announces Formation of Scientific Advisory Council
finance.yahoo.com - June 23 at 2:58 AM
americanbankingnews.com logo Brokerages Anticipate Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $213.55 Million
www.americanbankingnews.com - June 18 at 9:42 AM
finance.yahoo.com logoHaemonetics Will Webcast Investor and Analyst Meeting
finance.yahoo.com - June 14 at 7:06 PM
finance.yahoo.com logoHaemonetics Rides on Solid Plasma, Slows Blood Center Growth
finance.yahoo.com - June 14 at 7:06 PM
finance.yahoo.com logoHaemonetics Corp. :HAE-US: Earnings Analysis: Q4, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:50 AM
americanbankingnews.com logoHaemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 14 at 12:46 AM
finance.yahoo.com logoETFs with exposure to Haemonetics Corp. : June 13, 2017
finance.yahoo.com - June 13 at 5:24 PM

Social

Chart

Haemonetics Corporation (HAE) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff